Abstracts Archive - Page 36 of 2616 - ACR Meeting Abstracts

Abstract Number: 0388 • ACR Convergence 2025
A Scoping Review of Outcomes of Adults With Childhood-Onset Systemic Autoimmune Rheumatic Diseases
Michael Moore¹, Kaien Gu², Carol Cooke¹, Annaliese Tisseverasinghe¹ and Lily Lim¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) include systemic lupus erythematous (SLE), idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc), Sjögren syndrome (SS), and systemic vasculitis (SV).…
Abstract Number: 0295 • ACR Convergence 2025
Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Manali Sarkar¹, Meera Shah², Vincenzo Venerito³, Vikas Agarwal⁴ and Latika Gupta⁵, ¹Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ²Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Fatigue significantly impacts quality of life in idiopathic inflammatory myopathies (IIM) but remains poorly understood. This study aimed to identify the key determinants of…
Abstract Number: 0261 • ACR Convergence 2025
Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Daphne Guinn¹, Linchen He², Yuru Ren¹, Valeriy Korostyshevskiy¹ and Robert Beckman¹, ¹Georgetown University, Washington, ²Novartis, East Hanover
Background/Purpose: Basket trials group together participants who share a common biomarker or disease pathway across several diseases or phenotypes in a single clinical study. Such…
Abstract Number: 0348 • ACR Convergence 2025
Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
Karla Miller¹, Amani Jridi² and Tina Basak³, ¹University of Utah School of Medicine, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah Department of Radiology, Salt Lake City, UT
Background/Purpose: Rheumatoid arthritis (RA) patients are at higher risk of having generalized osteoporosis of the axial and appendicular skeleton assessed by dual-energy x-ray absorptiometry (DXA)…
Abstract Number: 0333 • ACR Convergence 2025
Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
Mohamed Abdelsalam¹, Hadeer Hafez², Omar Sameh Nabil El Sedafy¹, Nourhan Abouelella³, Ahmed Abdulhafeez Hamza³, Omnia Samy El-Sayed⁴, Mohamed Reda Awad⁵, Gihan Omar³ and Hazem E. Mohammed⁶, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²⁶th October University, ⁶ october, Al Jizah, Egypt, ³Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt, ⁶Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt
Background/Purpose: Artificial intelligence (AI) rapid advancement opens new opportunities in the field of rheumatology. With better imaging, AI may help find early osteoarthritic changes that…
Abstract Number: 0276 • ACR Convergence 2025
Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
Thomas Pelowitz, Benjamin Hur, Kenneth Warrington, Jaeyun Sung and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare fibroinflammatory disease of the retroperitoneum that can lead to obstructive uropathy and other life-threatening complications. While RPF can…
Abstract Number: 0362 • ACR Convergence 2025
Drug Persistence of IL-17A Inhibitors Among Patients with PsA: Real-World Data from the CorEvitas PsA/SpA Registry
Philip J. Mease¹, Nicole Middaugh², Maya Marchese³, Skyler Peterson³, Burcu Ertugrul Vardar⁴, Russel Burge⁵, Natalia Bello⁶, Marcus Ngantcha⁷, Joseph F Merola⁸, Louis Bessette⁹ and Alexis Ogdie¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, LLC, Waltham, ⁴Eli Lilly Cork GBS Ltd, Dublin, Dublin, Ireland, ⁵Eli Lilly and Company, Indianapolis, ⁶Eli Lilly, Indianapolis, IN, ⁷Eli Lilly GBS Cork Ltd, Cork, Ireland, ⁸Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: IL-17A inhibitors (IL-17Ai) are considered recommended biologic therapies for PsA per current treatment guidelines1,2. Real-world evidence (RWE) studies on IL-17Ai drug persistence among patients…
Abstract Number: 0260 • ACR Convergence 2025
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Lachelle D. Weeks¹, Danielle Hammond², Sinisa Savic³, Mael Heiblig⁴, Onima Chowdhury⁵, Arsène Mekinian⁶, Carmelo Gurnari⁷, Radhakrishanan Ramchandren⁸, Sophie georgin-Lavialle⁹, Marcela ferrada¹⁰, Sarah A. Buckley¹¹, Bryan G. harder¹¹, Sandra Goble¹¹, David Beck¹² and Matthew Koster¹³, ¹Dana Farber Cancer Institute, Boston, MA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁶Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁷Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁸University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁰University of Maryland, Bethesda, MD, ¹¹Sobi Inc., Waltham, MA, ¹²Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…
Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…
Abstract Number: 0363 • ACR Convergence 2025
Assessing Whole Health Needs in Systemic Lupus Erythematosus
Amanda Eudy¹, Megan Clowse², Dana Burshell³, Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Rebecca Sadun⁶, Ralph Snyderman⁷, Kai Sun⁶, Lisa Criscione-Schreiber³, Mithu Maheswaranathan³, Nathaniel Harris⁵, Jayanth Doss⁸ and Jennifer Rogers³, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, NC, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC
Background/Purpose: Care models that take a ‘Whole Health’ perspective by emphasizing personalized care focused on the individual’s values, needs, and goals, rather than solely on…
Abstract Number: 0359 • ACR Convergence 2025
“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid
Alicia Hamblin¹, Dylan Waller², Anaïs Tuepker², Catherine Nasrallah³, Alexandra Bennett², Brooke Jespersen², Joshua Baker⁴, Madhavi Valiveti⁵, gabriela Schmajuk⁶ and Jennifer Barton², ¹UCSF, San Francisco, CA, ²Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ³University of California San Francisco (UCSF), San Francisco, CA, ⁴Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) and University of Pennsylvania, Philadelphia, PA, ⁵VAMC Wilmington, Wilmington, DE, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Shared decision-making (SDM) is the first overarching principle of the treat-to-target guidelines for rheumatoid arthritis (RA). The quality of SDM varies widely, and its…
Abstract Number: 0364 • ACR Convergence 2025
Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey
Andreina Martinez Paulino¹, Miles King², Danny Arias Diaz¹, Asma Cheema³ and Muznay Khawaja⁴, ¹Jersey City Medical Center, Jersey City, NJ, ²Albert Einstein College of Medicine, New York, NY, ³Montefiore Einstein , Wakefield Campus, Woodbridge Township, NJ, ⁴Jersey City Medical Center, Hoboken, NJ

Background/Purpose: Clinical trials are the cornerstone of evidence-based rheumatology, yet enrolling and retaining a representative patient cohort remains challenging. While underrepresentation of underserved minorities is…
Abstract Number: 0325 • ACR Convergence 2025
Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
C. Kent Kwoh¹, Amanda Nelson², Rongrong Tang³, Edward J. Bedrick³, Yong Ge¹, Yvonne Golightly⁴, Zong-Ming Li³, Jean Liew⁵, Xiaoxiao Sun¹, Jeffrey Duryea⁶ and Tuhina Neogi⁵, ¹The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Boston University School of Medicine, Boston, MA, ⁶Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 0375 • ACR Convergence 2025
Association of Glucocorticoid Toxicity Index Scores with Quality-of-Life and Healthcare Resource Utilization at 6 Months in a Real-World Cohort of Individuals Receiving Glucocorticoids
Naomi Patel¹, Jiaqi Wang¹, Isha Jha², Grace McMahon¹, Tania Chiha³, Hyon K. Choi⁴ and John Stone⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Mount Auburn Hospital, Boston, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GCs) are used long-term by approximately 1% of the adult population and contribute to excess morbidity and mortality. We prospectively assessed Glucocorticoid Toxicity…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].